CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

Authors: Annick Desjardins, Vidya Chandramohan, James E II Herndon, Stevie Threatt, Chevelle Bullock, Claire Bradbury, Margaret O Johnson, Mustafa Khasraw, Justin T Low, Katherine B Peters, Madison Shoaf, Daniel Landi, Kristen Batich, Allan H Friedman, Henry S Friedman, David M Ashley, David Knorr, Juan Osorio, Jeffrey Ravetch, Darell D Bigner

Published: 2024-11-11

DOI: 10.1093/neuonc/noae165.0346

Source: Full article

CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

Abstract